LONGEVA.

CJC-1295 DAC: limits of adverse-reaction evidence

Teichman and colleagues’ abstract describes subcutaneous CJC-1295 in healthy adults across two trials lasting 28 and 49 days. No serious adverse reactions were reported. [1]

That does not mean no adverse reactions occurred. The abstract does not establish equivalence to a particular DAC/no-DAC product or batch, or long-term human safety. [1]

What the studies reported

EffectModel or participantsHow often or as describedSource
Serious adverse reactionsHealthy adults, subcutaneous administration, two trials lasting 28 and 49 daysNone were reported; that does not mean no adverse reactions occurred, and the abstract does not establish long-term safety[1]

References

  1. Teichman SL et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults https://doi.org/10.1210/jc.2005-1536.